Calcium;(3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Calcium;(3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate
• 化学式: C44H54CaF2N6O12S2
• 分子量: 1001.1
• InChiKey: LALFOYNTGMUKGG-VKLRDTKISA-L

计算性质

• 辛醇/水分配系数(LogP)：
  1.75
• 重原子数：
  67
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  304
• 氢给体数：
  4
• 氢受体数：
  20

反应信息

• 作为产物：
  描述：

  瑞舒伐他汀钠 以78的产率得到Calcium;(3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate
  参考文献：
  名称：

  USRE37314E1

  摘要：

  公开号：

文献信息

• Methods for predicting the response to statins
  申请人：Murata Glen H.

  公开号：US20110245283A1

  公开（公告）日：2011-10-06

  The invention provides methods for optimizing therapeutic efficacy for treating hypercholesterolemia in a subject having a cardiovascular disease (CVD), comprising (a) determining subject characteristics that affect the likelihood of reaching a goal level of low density lipoprotein (LDL); and (b) obtaining success probabilities of a variety of statin treatments for reaching said goal level of LDL using said subject characteristics and a multivariate model; and (c) administrating the optimal statin treatment with the highest success probability of step (b) to said subject thereby optimizing therapeutic efficacy for treating hypercholesterolemia in said subject.

  该发明提供了一种优化治疗高胆固醇血症的方法，用于治疗患有心血管疾病（CVD）的受试者，包括（a）确定影响达到低密度脂蛋白（LDL）目标水平可能性的受试者特征；和（b）利用受试者特征和多元模型获取各种他汀治疗达到所述LDL目标水平的成功概率；以及（c）向该受试者施用步骤（b）中具有最高成功概率的最佳他汀治疗，从而优化治疗高胆固醇血症的治疗效果。
• [EN] PROCESSES FOR THE PREPARATION OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE ROSUVASTATINE OU DE SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELLE-CI
  申请人：LAURUS LABS PRIVATE LTD

  公开号：WO2016125086A1

  公开（公告）日：2016-08-11

  The present invention relates to processes for the preparation of rosuvastatin calcium of formula I and pharmaceutically acceptable salts thereof using novel intermediates, and to a pharmaceutical composition containing the same.

  本发明涉及制备式I的瑞舒伐他汀钙及其药学上可接受的盐的新型中间体的过程，以及含有该物质的药物组合物。
• NOVEL METHOD FOR PREPARING ROSUVASTATIN, INTERMEDIATE COMPOUNDS USEFUL FOR PREPARING SAME, AND METHOD FOR PREPARING SAME
  申请人：Lee Hongwoo

  公开号：US20120136151A1

  公开（公告）日：2012-05-31

  The present invention relates to novel intermediate compounds used in preparing Rosuvastatin or the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a method for preparing Rosuvastatin or the pharmaceutically acceptable salts thereof from the intermediates. The preparation method of the present invention has the effect of providing Rosuvastatin hemi-calcium salts with an excellent yield rate.

  本发明涉及用于制备Rosuvastatin或其药用盐的新型中间化合物，以及制备相同的方法，以及从这些中间体制备Rosuvastatin或其药用盐的方法。本发明的制备方法具有提供具有优异产率的Rosuvastatin半钙盐的效果。
• [EN] ROSUVASTATIN INTERMEDIATES AND THEIR PREPARATION<br/>[FR] INTERMÉDIAIRES DE LA ROSUVASTATINE ET LEUR PRÉPARATION
  申请人：TEVA PHARMA

  公开号：WO2009009152A1

  公开（公告）日：2009-01-15

  Provided are processes and intermediates for preparation of rosuvastatin.

  提供了用于制备罗伐他汀的过程和中间体。
• [EN] PROCESS FOR THE PREPARATION OF ROSUVASTATIN<br/>[FR] PROCÉDÉ DE PRÉPARATION DE ROSUVASTATINE
  申请人：KRKA TOVARNA ZDRAVIL D D NOVO

  公开号：WO2010081861A1

  公开（公告）日：2010-07-22

  The invention relates to a process for the preparation of a HMG - CoA reductase inhibitor such as rosuvastatin, as well as intermediates useful in such process. The invention also relates to salts of HMG-CoA reductase inhibitors and processes for preparing same as well as processes for preparing pharmaceutically acceptable salts of HMG-CoA reductase inhibitors.

  该发明涉及一种用于制备类似罗伐他汀的HMG - CoA还原酶抑制剂的过程，以及在该过程中有用的中间体。该发明还涉及HMG-CoA还原酶抑制剂的盐以及制备其的过程，以及制备HMG-CoA还原酶抑制剂的药用可接受盐的过程。